BTG has completed the acquisition of Novate Medical and will add the vascular device Sentry to its portfolio.

Sentry is the first bioconvertible inferior vena cava filter used for managing blood clots. It features a bioconversion feature used for protecting patients against pulmonary embolism.

BTG plans for the US commercial launch of Sentry in the second half of the 2018-19 financial year.

Novate Medical’s acquisition follows the acquisition of cardiovascular speciality catheter maker Roxwood Medical in 2017.

Based in the UK, BTG is a healthcare company, while Novate Medical is an Ireland-based medical device company engaged in the development of inferior vena cava filters.

The transaction will enable BTG to strengthen its position in the vascular market, while offering its customers an innovative product for the management of pulmonary embolism.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

US-based medical devices manufacturer Boston Scientific has entered an agreement to acquire Augmenix for a cash consideration of $500m.

“The transaction will enable BTG to strengthen its position in the vascular market, while offering its customers an innovative product.”

Augmenix will receive up to $100m upon reaching sales-based milestones, as per the agreement.

The transaction is expected to be closed in the last quarter of 2019, subject to customary closing conditions.

Based in the US, Augmenix is a developer of hydrogel-based medical devices for radiation oncology and cancer surgery.

The acquisition will add Augmenix’s SpaceOAR system to Boston’s urology portfolio.

LimaCorporate has announced the acquisition of TechMah Medical for an undisclosed sum.

LimaCorporate will provide financing to TechMah Medical and complete the transaction by owning 100% of shares in TechMah Medical, upon achieving certain development targets.

Based in Italy, LimaCorporate specialises in orthopaedic solutions, while TechMah Medical is a US-based provider of orthopaedic solutions.

The transaction will enable the acquirer company to expand its presence in the orthopaedics market by adding the target company’s products to its hardware portfolio.